BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Figure 2 shows the cardiovascular considerations when selecting a TKI agent (18). Given the absence of biomarkers that predict the cardiovascular risk associated with BCR::ABL1 TKI therapy, traditional risk scores derived from the general population are usually used in CML patients as well. However, such scores may underestimate the risk (27).